Wearables accurately predict patient outcomes

A wrist-worn step tracker is an adequate tool to measure exercise capacity and the health status of patients, replacing a standardized six-minute walking test in a clinical setting, according to new research from Intermountain Healthcare.

The discovery illustrates how effective wearable technology has become in the medical field, enabling healthcare organizations to monitor patients remotely. The wearable space has become a hotbed for investments, and the market is expected to reach $54 billion in 2023.

Researchers from the not-for-profit healthcare organization––which is based in Salt Lake City and has 24 hospitals, a medical group with 2,400 physicians and advance care practice providers, 160 clinics and 38,000 employees––found that step trackers worn on the wrist delivered data that can be used to monitor patient progress and disease management.

A group of 52 patients wore wrist step counters for a period of 12 weeks, and patients also filled out respiratory symptom questionnaires. The group included adults with a history or respiratory problems. The findings were presented Sept. 29 at the European Respiratory Society International Congress in Madrid, Spain.

"For patients, this means we can track their progress more frequently in a manner that's less expensive and more convenient than current standardized testing," Denitza Blagev, MD, lead investigator of the study and pulmonary and critical care physician at Intermountain Healthcare, said in a statement.

The standardized testing known as the six-minute walk distance (6MWD) has been a baseline to assess exercise capacity by predicting outcomes and mortality for patients with chronic obstructive pulmonary disease and cardiovascular diseases based on how many meters they cover in six minutes of walking. With wrist-worn wearables giving more data to healthcare providers, patients can be monitored more frequently and without the need for a clinical setting.

“Now, we may be able to measure patients on a regular basis and know if we need to intervene if their estimated 6WMD by step count changes,” Blagev said.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.